Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Transcript
What are some novel therapies being used in the treatment of hematologic malignancies?
So, there are many examples of this. BCR-ABL is the prototypic example of precision medicine used for chronic myeloid leukemia (CML) with tyrosine kinase inhibitors, or TKIs. Acute myeloid leukemia (AML), which had not seen a lot of new therapies for decades, now has targeted therapies versus Flt3, versus IDH2, and we’re developing therapies for acute lymphoblastic leukemia (ALL), including Philadelphia-positive, just like CML.
And then in multiple myeloma, there have been limited reports of BRAF inhibition in myeloma. T(11;14) appears to be a marker for BCL-2 inhibition with venetoclax.
What biomarkers have you identified for deciding on a treatment approach for hematologic malignancies?
The biomarkers for treatment can either be prognostic, which we have a lot of biomarkers, or they can be predictive, which actually tells us that a drug is more likely to work in that area. My colleague has studied t(11;14) as a predictive biomarker in myeloma for effective venetoclax, and then we talked about BCR-ABL for Philadelphia-positive ALL for CML, and there are other emerging ones, so IDH2, Flt3 in AML.
Increasingly, people are trying to find other markers, which may be targets, and it’s somewhat theoretical sometimes, so FGFR in various hematologic malignancies. There’s JAK2 inhibition, but other JAK related pathways, so there’s a lot of emerging information. Some of these are in standard of practice. Some are almost becoming standard, and then others are still in the research category of trying to discover and implement new targeted therapies.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More